The international surgical journal with global reach

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double blind, phase 3 trial. Lancet 2014; 384: 319-328.

Published: 5th February 2015

Authors: Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L et al. et al.

Conclusion

In this multicentre trial that included 417 patients, sorafenib increased the median progression-free survival from 5.8 to 10.8 months (hazard ratio 0.59, 95 per cent confidence interval 0.45 to 0.76, P<0.0001).

Pubmed Link